دورية أكاديمية
أعرض في EDS

Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update.

التفاصيل البيبلوغرافية
العنوان: Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update.
المؤلفون: Ferreira C; Institute of Pharmacology & Experimental Therapeutics, & Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.; Clinical Academic Center of Coimbra (CACC), 3000-075 Coimbra, Portugal., Viana SD; Institute of Pharmacology & Experimental Therapeutics, & Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.; Clinical Academic Center of Coimbra (CACC), 3000-075 Coimbra, Portugal.; Polytechnic Institute of Coimbra, ESTESC-Coimbra Health School, Pharmacy, 3046-854 Coimbra, Portugal., Reis F; Institute of Pharmacology & Experimental Therapeutics, & Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.; Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3004-504 Coimbra, Portugal.; Clinical Academic Center of Coimbra (CACC), 3000-075 Coimbra, Portugal.
المصدر: Microorganisms [Microorganisms] 2020 Dec 28; Vol. 9 (1). Date of Electronic Publication: 2020 Dec 28.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101625893 Publication Model: Electronic Cited Medium: Print ISSN: 2076-2607 (Print) Linking ISSN: 20762607 NLM ISO Abbreviation: Microorganisms Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: The scientific knowledge already attained regarding the way severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells and the clinical manifestations and consequences for Coronavirus Disease 2019 (COVID-19) patients, especially the most severe cases, brought gut microbiota into the discussion. It has been suggested that intestinal microflora composition plays a role in this disease because of the following: (i) its relevance to an efficient immune system response; (ii) the fact that 5-10% of the patients present gastrointestinal symptoms; and (iii) because it is modulated by intestinal angiotensin-converting enzyme 2 (ACE2) (which is the virus receptor). In addition, it is known that the most severely affected patients (those who stay longer in hospital, who require intensive care, and who eventually die) are older people with pre-existing cardiovascular, metabolic, renal, and pulmonary diseases, the same people in which the prevalence of gut microflora dysbiosis is higher. The COVID-19 patients presenting poor outcomes are also those in which the immune system's hyperresponsiveness and a severe inflammatory condition (collectively referred as "cytokine storm") are particularly evident, and have been associated with impaired microbiota phenotype. In this article, we present the evidence existing thus far that may suggest an association between intestinal microbiota composition and the susceptibility of some patients to progress to severe stages of the disease.
References: Front Immunol. 2019 Jul 04;10:1551. (PMID: 31333675)
Biochim Biophys Acta Mol Basis Dis. 2019 Jul 1;1865(7):1876-1897. (PMID: 30287404)
Lancet Rheumatol. 2020 Jul;2(7):e428-e436. (PMID: 32835246)
Clin Infect Dis. 2020 Jun 04;:. (PMID: 32497191)
Cell Death Discov. 2020 Aug 11;6:76. (PMID: 32818075)
J Clin Virol. 2020 Jun;127:104354. (PMID: 32305882)
Circ J. 2013;77(2):301-8. (PMID: 23328447)
Front Immunol. 2020 Oct 08;11:589380. (PMID: 33178221)
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):644-645. (PMID: 32339473)
Front Microbiol. 2020 Jun 05;11:1302. (PMID: 32582134)
Anaesthesiol Intensive Ther. 2020;52(2):171-172. (PMID: 32200613)
Cell Res. 2020 Jun;30(6):492-506. (PMID: 32433595)
World J Gastroenterol. 2015 Aug 7;21(29):8787-803. (PMID: 26269668)
Nutrients. 2020 Feb 26;12(3):. (PMID: 32110880)
Intensive Care Med. 2016 Jun;42(6):1018-28. (PMID: 27043237)
Cell. 2016 Nov 3;167(4):1125-1136.e8. (PMID: 27814509)
Clin Infect Dis. 2020 Jul 28;71(15):762-768. (PMID: 32161940)
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):721-722. (PMID: 32673604)
Lancet Respir Med. 2020 Dec;8(12):1201-1208. (PMID: 32861276)
Eur Rev Med Pharmacol Sci. 2020 Oct;24(20):10853-10859. (PMID: 33155247)
BMJ Nutr Prev Health. 2020 May 20;3(1):74-92. (PMID: 33230497)
J Med Invest. 2016;63(1-2):27-37. (PMID: 27040049)
Philos Trans R Soc Lond B Biol Sci. 2020 Sep 28;375(1808):20190594. (PMID: 32772673)
Gut. 2020 Jun;69(6):1002-1009. (PMID: 32213556)
Front Immunol. 2020 Jul 10;11:1708. (PMID: 32754163)
Gut Microbes. 2012 Jan-Feb;3(1):4-14. (PMID: 22356853)
Front Physiol. 2019 Apr 16;10:428. (PMID: 31057420)
Virus Res. 2020 Aug;285:198018. (PMID: 32430279)
Nutrients. 2019 Dec 27;12(1):. (PMID: 31892152)
Ageing Res Rev. 2020 Sep;62:101091. (PMID: 32454090)
Biochem J. 2017 May 16;474(11):1823-1836. (PMID: 28512250)
Cell. 2014 Mar 27;157(1):121-41. (PMID: 24679531)
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. (PMID: 20522788)
J Infect. 2020 Aug;81(2):318-356. (PMID: 32283159)
Ageing Res Rev. 2020 Sep;62:101123. (PMID: 32683039)
J Clin Virol. 2020 Jun;127:104357. (PMID: 32305884)
Semin Immunopathol. 2017 Jul;39(5):529-539. (PMID: 28466096)
Gut Microbes. 2020 Jul 3;11(4):900-917. (PMID: 31973685)
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):629-630. (PMID: 32405602)
Front Immunol. 2018 Aug 15;9:1830. (PMID: 30158926)
Signal Transduct Target Ther. 2020 Mar 27;5(1):33. (PMID: 32296069)
Signal Transduct Target Ther. 2020 May 29;5(1):84. (PMID: 32467561)
Clin Gastroenterol Hepatol. 2021 Jan;19(1):206. (PMID: 32712394)
mBio. 2020 Feb 18;11(1):. (PMID: 32071269)
Front Immunol. 2018 Nov 16;9:2640. (PMID: 30505304)
Clin Exp Immunol. 2020 Jul;201(1):76-84. (PMID: 32365221)
J Dig Dis. 2020 Apr;21(4):199-204. (PMID: 32267098)
Prog Mol Biol Transl Sci. 2020;171:15-60. (PMID: 32475521)
Infect Dis Poverty. 2020 Aug 3;9(1):108. (PMID: 32746940)
Immunol Lett. 2020 Sep;225:31-32. (PMID: 32569607)
Microorganisms. 2020 Oct 01;8(10):. (PMID: 33019592)
mSystems. 2020 Jul 21;5(4):. (PMID: 32694127)
Nat Rev Microbiol. 2017 Jan;15(1):55-63. (PMID: 27694885)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Front Immunol. 2020 May 01;11:827. (PMID: 32425950)
Med J Aust. 2020 Jul;213(2):54-56.e1. (PMID: 32572965)
Microbes Infect. 2013 Nov;15(13):866-73. (PMID: 23962453)
Gastroenterology. 2020 Jun;158(8):2298-2301.e7. (PMID: 32234303)
PeerJ. 2019 Aug 16;7:e7502. (PMID: 31440436)
Gastroenterology. 2021 Jan;160(1):39-46. (PMID: 33130103)
Gastroenterology. 2020 Sep;159(3):944-955.e8. (PMID: 32442562)
ACS Nano. 2020 May 26;14(5):5179-5182. (PMID: 32356654)
J Infect Public Health. 2020 Nov;13(11):1619-1629. (PMID: 32718895)
NPJ Sci Food. 2020 Oct 5;4:17. (PMID: 33083549)
Inflamm Regen. 2020 Oct 1;40:37. (PMID: 33014208)
Curr Opin Virol. 2011 Dec;1(6):463-75. (PMID: 22440910)
Gut. 2021 Feb;70(2):276-284. (PMID: 32690600)
Front Cell Infect Microbiol. 2020 Feb 19;10:9. (PMID: 32140452)
Aging Dis. 2020 May 13;11(4):874-894. (PMID: 32765952)
Nature. 2012 Jul 25;487(7408):477-81. (PMID: 22837003)
Nutrients. 2019 Sep 13;11(9):. (PMID: 31540270)
Int J Infect Dis. 2020 Oct;99:92-99. (PMID: 32758688)
Cell. 2017 Feb 23;168(5):928-943.e11. (PMID: 28215708)
Microb Ecol Health Dis. 2015 Feb 02;26:26191. (PMID: 25651997)
J Intensive Care. 2020 May 24;8:36. (PMID: 32483488)
Cell Biol Int. 2020 Sep;44(9):1792-1797. (PMID: 32458561)
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346. (PMID: 32214079)
Cell. 2020 Jul 9;182(1):59-72.e15. (PMID: 32492406)
Cell Microbiol. 2018 Dec;20(12):e12966. (PMID: 30329198)
Am J Respir Crit Care Med. 2020 Mar 1;201(5):555-563. (PMID: 31973575)
Therap Adv Gastroenterol. 2013 Jul;6(4):295-308. (PMID: 23814609)
Transl Res. 2020 Dec;226:57-69. (PMID: 32827705)
معلومات مُعتمدة: UIDP/04539/2020 (CIBB); PTDC/SAU-NUT/31712/2017, POCI-01-0145-FEDER-007440, POCI-01-0145-FEDER-031712, and CENTRO-01-0145-FEDER-000012-HealthyAging2020 FCT-FEDER-COMPETE
فهرسة مساهمة: Keywords: COVID-19; gut microbiota dysbiosis; immune response; inflammation; susceptibility to progress
تواريخ الأحداث: Date Created: 20201231 Latest Revision: 20210126
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7824665
DOI: 10.3390/microorganisms9010053
PMID: 33379162
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-2607
DOI:10.3390/microorganisms9010053